Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Better access to high quality biological medicines
The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars

The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars.

The members of the BBA ensure access to high quality, safe and effective biosimilar medicines for UK patients. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and continuing optimised use of biosimilar medicines across the UK.

For more information about Biosimilars, please take a look at NHS England’s ‘What is a Biosimilar’ document.

Twitter

17.05.2018
RT @Britishgenerics: Read our reaction to the @beisgovuk report on the impact of Brexit on the pharmaceutical sector - we agree patients could be impacted by lack of deal https://t.co/IqvDngb6zh
09.05.2018
RT @theGHS: In the latest issue of Today’s Pharmacist, director general @BritBiosimilars, Warwick Smith, outlines the challenges and opportunities for biosimilar medicines in the UK, making the business and professional case for their use in the NHS: https://t.co/L3Xf18KEjf #TodaysPharmaci
27.04.2018
RT @UK_Life_Science: Speech made by Simon Stevens @NHSEngland on biosimilars at #ABPIConf : The desire for the UK to be the fastest adopter where these drugs offer better value than comparators https://t.co/22SVTr3uLi
27.04.2018
RT @ScripIanS: NHS is "looking forward to autumn" when biosimilars of AbbVie's Humira (adalimumab) become available - procurement strategies are being drawn up now, Keith Ridge, Chief Pharmaceutical Officer of NHS England, tells Medicines for Europe biosimilars conference
27.04.2018
RT @ScripIanS: On May 23rd the @EU_Commission will discuss whether to press ahead with draft legislation allowing an SPC manufacturing waiver for generics/bioismilars intended for non-EU markets. Move welcomed by president of Medicines for Europe @medicinesforEU conference.